Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
J Clin Immunol ; 35(2): 199-205, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25663093

ABSTRACT

INTRODUCTION: Complement immunodeficiencies (excluding hereditary angioedema and mannose binding lectin deficiency) are rare. Published literature consists largely of case reports and small series. We collated data from 18 cities across Europe to provide an overview of primarily homozygous, rather than partial genotypes and their impact and management. METHODS: Patients were recruited through the ESID registry. Clinical and laboratory information was collected onto standardized forms and analyzed using SPSS software. RESULTS: Seventy-seven patients aged 1 to 68 years were identified. 44 % presented in their first decade of life. 29 % had C2 deficiency, defects in 11 other complement factors were found. 50 (65 %) had serious invasive infections. 61 % of Neisseria meningitidis infections occurred in patients with terminal pathway defects, while 74 % of Streptococcus pneumoniae infections occurred in patients with classical pathway defects (p < 0.001). Physicians in the UK were more likely to prescribe antibiotic prophylaxis than colleagues on the Continent for patients with classical pathway defects. After diagnosis, 16 % of patients suffered serious bacterial infections. Age of the patient and use of prophylactic antibiotics were not associated with subsequent infection risk. Inflammatory/autoimmune diseases were not seen in patients with terminal pathway, but in one third of patients classical and alternative pathway defects. CONCLUSION: The clinical phenotypes of specific complement immunodeficiencies vary considerably both in terms of the predominant bacterial pathogen, and the risk and type of auto-inflammatory disease. Appreciation of these phenotypic differences should help both immunologists and other specialists in their diagnosis and management of these rare and complex patients.


Subject(s)
Complement System Proteins/deficiency , Complement System Proteins/genetics , Immunologic Deficiency Syndromes/epidemiology , Immunologic Deficiency Syndromes/genetics , Adolescent , Adult , Aged , Child , Child, Preschool , Complement Activation/genetics , Complement Activation/immunology , Complement System Proteins/immunology , Consanguinity , Databases, Factual , Disease Management , Europe/epidemiology , Female , Genotype , Humans , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/therapy , Infant , Male , Middle Aged , Young Adult
3.
Klin Padiatr ; 226(3): 133-42, 2014 May.
Article in English | MEDLINE | ID: mdl-24819385

ABSTRACT

Most of the autoinflammatory diseases (AID) are orphan diseases with recurrent episodes of systemic inflammation. Fever and exanthema are leading features. Given the ongoing elucidation of pathogenic causes and hence therapeutic approaches, we provided a review of the current literature of AID.


Subject(s)
Adaptive Immunity/immunology , Hereditary Autoinflammatory Diseases/diagnosis , Rare Diseases , Adaptive Immunity/genetics , Child , DNA Mutational Analysis , Diagnosis, Differential , Genetic Diseases, Inborn/diagnosis , Genetic Diseases, Inborn/genetics , Genetic Diseases, Inborn/immunology , Genetic Diseases, Inborn/therapy , Genotype , Hereditary Autoinflammatory Diseases/classification , Hereditary Autoinflammatory Diseases/immunology , Hereditary Autoinflammatory Diseases/therapy , Humans , Immunity, Innate/genetics , Immunity, Innate/immunology
4.
Klin Padiatr ; 225(6): 325-30, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24158885

ABSTRACT

Familial Mediterranean fever (FMF) is the most inherited common autoinflammatory disease (AID) with mutations in the MEFV (MEditerraneanFeVer) gene.The Mor- and Pras-Score modified for children and C-reactive protein (CRP) were used to assess FMF disease severity in Germany. We evaluate the applicability of the 2 severity scores and the correlations between ethnic origin, phenotype, and genotype.Among 242 children (median 5 age at diagnosis), we detected 431 pyrin mutations and 22 different sequence variants, including one new mutation (p.Gly488Asp). The 5 most -frequent alterations were p.Met694Val (55.2%), p.Met680lle (11.8%), p.Val726Ala (10%), p.Glu148Gln (7.9%) and p.Met694IIe (2.3%). The prevailing ancestries of 223 cases were Turkish (82.5%) and Lebanese (8.1%). Homozygous p.Met694Val substitution (30.2%) was associated with a more severe disease activity by Mor-Score, as well as with a higher mean CRP (74 mg/l) compared to patients with other mutations. Indeed, Mor- and Pras-Score were inconsistent with each other. A typical distribution of mutations in different ethnic populations was obvious, but not statistically verifiable due to the low number of cases.The homozygous p.Met694Val substitution was associated with a more severe disease activity in our German cohort. The common severity scores were inconsistent in -children.


Subject(s)
Familial Mediterranean Fever/diagnosis , Familial Mediterranean Fever/genetics , Genotype , Phenotype , Adolescent , Alleles , Amino Acid Substitution/genetics , C-Reactive Protein/metabolism , Child , Child, Preschool , Cohort Studies , Cytoskeletal Proteins/genetics , DNA Mutational Analysis , Familial Mediterranean Fever/ethnology , Female , Gene Frequency/genetics , Germany , Homozygote , Humans , Infant , Lebanon/ethnology , Male , Methionine/genetics , Pyrin , Registries , Turkey/ethnology , Valine/genetics
5.
Clin Exp Immunol ; 173(2): 372-80, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23607573

ABSTRACT

In 2009, a federally funded clinical and research consortium (PID-NET, http://www.pid-net.org) established the first national registry for primary immunodeficiencies (PID) in Germany. The registry contains clinical and genetic information on PID patients and is set up within the framework of the existing European Database for Primary Immunodeficiencies, run by the European Society for Primary Immunodeficiencies. Following the example of other national registries, a central data entry clerk has been employed to support data entry at the participating centres. Regulations for ethics approvals have presented a major challenge for participation of individual centres and have led to a delay in data entry in some cases. Data on 630 patients, entered into the European registry between 2004 and 2009, were incorporated into the national registry. From April 2009 to March 2012, the number of contributing centres increased from seven to 21 and 738 additional patients were reported, leading to a total number of 1368 patients, of whom 1232 were alive. The age distribution of living patients differs significantly by gender, with twice as many males than females among children, but 15% more women than men in the age group 30 years and older. The diagnostic delay between onset of symptoms and diagnosis has decreased for some PID over the past 20 years, but remains particularly high at a median of 4 years in common variable immunodeficiency (CVID), the most prevalent PID.


Subject(s)
Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/epidemiology , Registries , Adolescent , Adult , Age Factors , Aged , Child , Child, Preschool , Databases, Factual , Female , Germany , Humans , Immunologic Deficiency Syndromes/genetics , Infant , Infant, Newborn , Male , Middle Aged , Prevalence , Young Adult
6.
Klin Padiatr ; 224(6): 404-15, 2012 Oct.
Article in German | MEDLINE | ID: mdl-23143768

ABSTRACT

BACKGROUND: Currently, management of antibody deficient patients differs significantly among caregivers. Evidence and consensus based (S3) guidelines for the treatment of primary antibody deficiencies were developed to improve the management of these patients. METHODS: Based on a thorough analysis of current evidence (systematic literature search in PubMed; deadline November 2011) 14 recommendations were finalized during a consensus meeting in Frankfurt in November 2011 using structured consensus methods (nominal group technique). Experts were nominated by their scientific societies/patient initiatives (Tab. 1). RESULTS: The guidelines focus on indication, practical issues and monitoring of immunoglobulin replacement therapy as well as on different routes of administration. Furthermore recommendations regarding supportive measures such as antiinfective therapy, vaccinations and physiotherapy are given. Combining literature evidence and experience of caregivers within this evidence and consensus based guidelines offers the chance to improve the quality of care for anti-body deficient patients.


Subject(s)
Cooperative Behavior , Immunologic Deficiency Syndromes/therapy , Interdisciplinary Communication , Adult , Anti-Infective Agents/therapeutic use , Child, Preschool , Combined Modality Therapy , Evidence-Based Medicine , Humans , Immunization, Passive , Physical Therapy Modalities , Quality Improvement , Randomized Controlled Trials as Topic , Vaccination
7.
Klin Padiatr ; 223(6): 386-94, 2011 Nov.
Article in German | MEDLINE | ID: mdl-22012606

ABSTRACT

BACKGROUND: Treatment of Juvenile Idiopathic Arthritis (JIA) has improved quality of life in children and adolescents with JIA. Standardisation of care offers the chance to improve the quality of care of those patients. New studies have been published after completion of our last treatment guideline (2007). An updated consensus process is mandatory. METHODS: A systematic literature analysis in PUBMED (key words: juvenile idiopathic (rheumatoid) arthritis, therapy; limits: humans, published in the last 3 years, all child 0-18 years, clinical trial) revealed 17 relevant studies. Studies relating to diagnosis of JIA, Uveitis, vaccination, transition were excluded. Representatives nominated by scientific societies and organisations were invited to consensus conferences which were hosted by a professional moderator. The following societies were invited: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Consensus conferences were each attended by more than 95% of the nominated representatives. Consensus statements were confirmed by nominal group technique and Delphi method. RESULTS AND CONCLUSION: Updated consensus statements regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).


Subject(s)
Arthritis, Juvenile/therapy , Cooperative Behavior , Evidence-Based Medicine , Interdisciplinary Communication , Adolescent , Anti-Inflammatory Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/diagnosis , Biological Products/therapeutic use , Child , Child, Preschool , Combined Modality Therapy , Germany , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Infant , Occupational Therapy , Physical Therapy Modalities
8.
Clin Immunol ; 137(3): 357-65, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20832369

ABSTRACT

Autoimmune lymphoproliferative syndrome (ALPS) is mainly caused by defects in the CD95 pathway. Raised CD3+TCRαß+CD4-CD8- double negative T cells and impaired T cell apoptosis are hallmarks of the disease. In contrast, the B cell compartment has been less well studied. We found an altered distribution of B cell subsets with raised transitional B cells and reduced marginal zone B cells, switched memory B cells and plasma blasts in most of 22 analyzed ALPS patients. Moreover, 5 out of 66 ALPS patients presented with low IgG and susceptibility to infection revealing a significant overlap between ALPS and common variable immunodeficiency (CVID). In patients presenting with lymphoproliferation, cytopenia, hypogammaglobulinemia and impaired B cell differentiation, serum biomarkers were helpful in addition to apoptosis tests for the identification of ALPS patients. Our observations may indicate a role for apoptosis defects in some diseases currently classified as CVID.


Subject(s)
Autoimmune Lymphoproliferative Syndrome/diagnosis , Autoimmune Lymphoproliferative Syndrome/immunology , B-Lymphocytes/immunology , Common Variable Immunodeficiency/diagnosis , Common Variable Immunodeficiency/immunology , Fas Ligand Protein/blood , Interleukin-10/blood , Vitamin B 12/blood , Adolescent , Adult , Agammaglobulinemia/immunology , Apoptosis , Biomarkers/blood , Child , Child, Preschool , Diagnosis, Differential , Fas Ligand Protein/immunology , Flow Cytometry , Humans , Immunoglobulin G/blood , Interleukin-10/immunology , Middle Aged , Monocytes/immunology , Phenotype , T-Lymphocytes/immunology , Vitamin B 12/immunology , fas Receptor/blood , fas Receptor/immunology
9.
Bone Marrow Transplant ; 33(8): 815-21, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14990984

ABSTRACT

Children with leukemias and increasing mixed chimerism (increasing MC) after allogeneic stem cell transplantation have the highest risk to relapse. Early immunological intervention was found to be effective in these cases. To substantiate this on a defined group of pediatric acute myelogenous leukemia (AML) patients, we performed serial analysis of post transplant chimerism and pre-emptive immunotherapy in patients with increasing MC. In total, 81 children were monitored, 62 patients revealed complete chimerism (CC), low-level MC or decreasing MC. Increasing MC was detected in 19 cases. Despite early immunological intervention relapse was still significantly more frequent in patients with increasing MC (9/19) than in patients with CC, low-level or decreasing MC (8/62, P<0.005). The probability of 3-year event-free survival (EFS) was 52% for all patients (n=81), 59% for patients with CC, low-level MC, 60% for patients with decreasing MC (n=62), and 28% for patients with increasing MC (n=19, P<0.005). Patients with increasing MC who received early immunological intervention showed a significantly enhanced probability for event-free survival (pEFS 36%, n=15) compared to patients with increasing MC without intervention (pEFS 0%, n=4, P<0.05). These results prove that pediatric AML patients with increasing MC are at highest risk for relapse and that early immunological intervention can prevent relapse in these patients.


Subject(s)
Hematopoietic Stem Cell Transplantation , Immunotherapy , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/therapy , Transplantation Chimera/genetics , Adolescent , Adult , Child , Child, Preschool , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Infant , Lymphocyte Transfusion , Male , Prospective Studies , Risk Factors , Tissue Donors , Transplantation, Homologous
10.
Bone Marrow Transplant ; 33(2): 219-23, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14647253

ABSTRACT

Allogeneic stem cell transplantation (allo-SCT) is a well-established treatment modality for children with severe aplastic anemia (SAA). Treatment failures are rare and mostly caused by graft rejection. Increasing mixed chimerism represents a stage at the very beginning of graft rejection, where immunological intervention might be an effective prophylactic approach. To substantiate this, we: (1) monitored peripheral blood cells from children with SAA after allo-SCT and performed pre-emptive immunotherapy in patients with increasing MC. In all, 23/34 courses of 32 children with SAA after allo-SCT showed a complete chimerism (CC) throughout and 10/34 developed different types of mixed chimerism (MC). Altogether, 4/10 with MC spontaneously developed decreasing MC, 2/10 courses persisted with low proportions of autologous cells below 30% (stable-MC), 4/10 developed increasing MC and one patient showed an autologous recovery. All patients with CC, decreasing MC or stable MC remained in continuous complete remission (CCR). In all, 2/4 patients with increasing MC developed graft rejection. Based on these observations, 2/4 new patients with increasing MC received low-dose DLIs prophylactically, and remained in CCR without any GVHD. These results substantiate that low-dose DLI in children with SAA and increasing MC can prevent graft rejection with a calculable risk to induce severe GVHD.


Subject(s)
Anemia, Aplastic/therapy , Hematopoietic Stem Cell Transplantation , Transplantation Chimera , Adolescent , Child , Child, Preschool , Graft Rejection/drug therapy , Graft Rejection/epidemiology , Graft Rejection/prevention & control , Graft vs Host Disease/drug therapy , Graft vs Host Disease/epidemiology , Humans , Immunosuppressive Agents/therapeutic use , Phenotype , Risk Factors , Severity of Illness Index , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...